

Docket No.: 0933-0241PUS1

(PATENT)

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of: Jukka T. SALONEN et al.

Application No.: Not Yet Assigned

Confirmation No.: N/A

Filed: April 6, 2005

Art Unit: N/A

For: DETECTING THE RISK OF

CARDIOVASCULAR DISEASE BY DETECTING MUTATIONS IN GENES, INCLUDING GENES ENCODING A2B-

ADRENOCEPTOR AND APOLIPOPROTEIN B

Examiner: Not Yet Assigned

## **INFORMATION DISCLOSURE STATEMENT (IDS)**

MS PCT Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

Copies of the references on the PTO/SB/08 are not provided.



JOYS ROLL TOPTO 0 G APR 2005

Application No.: Not Yet Assigned

Docket No.: 0933-0241PUS1

Those documents which are marked with a double asterisk (\*\*) next to the Cite No. in the attached form PTO/SB/08 (facsimile) are not supplied because they were previously cited by or submitted to the Office in a prior application number PCT/FI2003/000740, filed October 7, 2003.

A concise explanation of relevance of the items listed on form PTO/SB/08 is in the form of an English language copy of a Search Report from a foreign patent office, issued in a counterpart application, which refers to the relevant portions of the references.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.



Application No.: Not Yet Assigned

Docket No.: 0933-0241PUS1

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: April 6, 2005

GMM/nl

Respectfully submitted,

Registration No.: 28,977

BIRCH, STEWART, KÓLÁSCH & BIRCH, LLP

8110 Gatehouse Rd

Suite 100 East

P.O. Box 747 Falls Church, Virginia 22040-0747

(703) 205-8000

Attorney for Applicant



## JC13 Re CT/PTO 0 6 APR 2003

PTO/SB/08a/b (08-03)
Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/B/PTO				Complete if Known		
				Application Number	Not Yet Assigned	
l II	<b>NFORMATIO</b>	N DISC	LOSURE	Filing Date	April 6, 2005	
S	STATEMENT BY APPLICANT			First Named Inventor	Jukka T. SALONEN	
				Art Unit	N/A	
(Use as many she ets as necessary)			ess ary)	Examiner Name	Not Yet Assigned	
Sheet	1	of	1	Attorney Docket Number	0933-0241PUS1	

U.S. PATENT DOCUMENTS						
Examiner Initials*	Cite No. <sup>1</sup>	Document Number  Number-Kind Code <sup>2</sup> ( if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	

FOREIGN PATENT DOCUMENTS						
Examiner	Cite	Foreign Patent Document	Publication	Name of Patentee or	Pages, Columns, Lines,	
Initials*	No.'	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> (if known)	Date MM-DD-YYYY	Applicant of Cited Document	Where Relevant Passages or Relevant Figures Appear	T⁵
	BA**	WO-0129082-A1	04-26-2001			

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\* CITE NO.: Those document(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120. \*I Applicant's unique citation designation number (optional). \*See Kinds Codes of USPTO Patent Documents at <a href="https://www.uspto.gov">www.uspto.gov</a> or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \*For Japanese patent documents, the Indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Skind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language Translation is attached.

		NON PATENT LITERATURE DOCUMENTS	
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	CA**	Pallaud et al., "Genetic influences on lipid metabolism trait variability within the Stanislas Cohort", Journal of Lipid Research, Volume 42, 2001, pages 1879-1890.	
	CB**	Snapir et al., "An insertion/deletion polymorphism in the apha2B-adrenergic receptor gene is a novel genetic risk factor for actue coronary events", Journal of the American College of Cardiology, Volume 37, No. 6, 2001, pages 1516-1522.	
	CC**	Guzman et al., "Association of the apolipoprotein B gene polymorphisms with cholesterol levels and response to fluvastatin in Brazilian individuals with high risk for coronary heart disease", BIOSIS, accession no. PREV200000525011, Clinical Chemistry and Laboratory Medicine, August 2000, Vol. 38, No. 8, pages 731-736.	
	CD**	Zee et al., "Short communication, genes & genetics satellite of the 15th ISH meeting: Frequencies of variants of candidate genes in different age groups of hypertensives", Clinical and Experimental Pharmacology and Physiology, Vol. 21, 1994, pages 925-930.	·
	CE**	Morris et al., "Independent, marked association of alleles of the insulin receptor and dipeptidyl carboxypeptidase I genes with essential hypertension", BIOSIS, accession no. PREV199396108513, Clinical Science, London, 1993, Vol. 85, No. 2, pages 189-195.	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. \*\* CITE NO.: Those document(s) which are marked with an double asterisk (\*\*) next to the Cite No. are not supplied because they were previously cited by or submitted to the Office in a prior application relied upon in this application for an earlier filing date under 35 U.S.C. 120.

'Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner	Date	
Signature	Considered	